Your Health. Your Family. Your Choice.
Life Threatening? No
Write-up: invasive group B ?meningococcal disease; This case was reported by a other health professional via local affiliate and described the occurrence of meningococcal bacteremia in a 3-month-old female patient who received Men B NVS (Bexsero) (batch number 167301, expiry date unknown) for prophylaxis. On 26th March 2018, the patient received the 1st dose of Bexsero. On 21st May 2018, 56 days after receiving Bexsero, the patient experienced meningococcal bacteremia (serious criteria death and GSK medically significant). On an unknown date, the outcome of the meningococcal bacteremia was fatal. It was unknown if the reporter considered the meningococcal bacteremia to be related to Bexsero. Additional details were provided as follows: This case was received from health care professional (HCP) via GlaxoSmithKline (GSK) employee. Age at vaccination was not reported. The reporter stated that the patient died from invasive group B meningococcal disease. In accordance with the national immunisation programme for Meningococcal B vaccination, the patient was vaccinated with a dose of Bexsero. No other information was provided. Follow up would be sent.
Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166